Evidence map›Paper›PMID 38759125›Full record

ArticleJCO clinical cancer informatics2024

Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer Database.

Neal Bhutiani, Mahmoud M G Yousef, Abdelrahman Yousef, Mohammad Zeineddine, Mark Knafl, Olivia Ratliff, Uditha P Fernando, Anastasia Turin, Fadl A Zeineddine, Jeff Jin and 6 more

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Neal BhutianiDepartment of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6288-2788
Mahmoud M G YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0007-2550-4837
Abdelrahman YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7761-8149
Mohammad ZeineddineDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-8075-765X
Mark KnaflDepartment Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3953-2173
Olivia RatliffInformation Services, Enterprise Development & Integration, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0002-6196-771X
Uditha P FernandoInformation Services, Enterprise Development & Integration, The University of Texas MD Anderson Cancer Center, Houston, TX.
Anastasia TurinInformation Services, Enterprise Development & Integration, The University of Texas MD Anderson Cancer Center, Houston, TX.
Fadl A ZeineddineDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jeff JinInformation Services, Enterprise Development & Integration, The University of Texas MD Anderson Cancer Center, Houston, TX.
Kristin Alfaro-MunozDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-9870-8415
Drew GoldsteinSyntropy Technologies LLC, Cambridge, MA.
George J ChangDepartment of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-9758-5361
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9647-3416
John Paul ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4588-2775
Abhineet UppalDepartment of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-0762-3457

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3M
High-Throughput Functional Genomics to Guide Precision Oncology in Gastrointestinal TumorsK22CA234406 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEN, JOHN PAUL YING CHING · 2019 to 2021
$577k
NCATS NIH HHS KL2 TR000370NCI NIH HHS K22 CA234406NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

purposeDynamic operations platforms allow for cross-platform data extraction, integration, and analysis, although application of these platforms to large-scale oncology enterprises has not been described. This study presents a pipeline for automated, high-fidelity extraction, integration, and validation of cross-platform oncology data in patients undergoing treatment for rectal cancer at a single, high-volume institution.

methodsA dynamic operations platform was used to identify patients with rectal cancer treated at MD Anderson Cancer Center between 2016 and 2022 who had magnetic resonance imaging (MRI) imaging and preoperative treatment details available in the electronic health record (EHR). Demographic, clinicopathologic, tumor mutation, radiographic, and treatment data were extracted from the EHR using a methodology adaptable to any disease site. Data accuracy was assessed by manual review. Accuracy before and after implementation of synoptic reporting was determined for MRI data.

resultsA total of 516 patients with localized rectal cancer were included. In the era after institutional adoption of synoptic reports, the dynamic operations platform extracted T (tumor) category data from the EHR with 95% accuracy compared with 87% before the use of synoptic reports, and N (lymph node) category with 88% compared with 58%. Correct extraction of pelvic sidewall adenopathy was 94% compared with 78%, and extramural vascular invasion accuracy was 99% compared with 89%. Neoadjuvant chemotherapy and radiation data were 99% accurate for patients who had synoptic data sources.

conclusionUsing dynamic operations platforms enables automated cross-platform integration of multiparameter oncology data with high fidelity in patients undergoing multimodality treatment for rectal cancer. These pipelines can be adapted to other solid tumors and, together with standardized reporting, can increase efficiency in clinical research and the translation of actionable findings toward optimizing patient outcomes.

Indexed as

Databases, FactualMagnetic Resonance ImagingRectal NeoplasmsAdultAgedElectronic Health RecordsFemaleHumansMaleMiddle AgedNeoplasm StagingReproducibility of Results

Identifiers

PMID38759125
PMCPMC12123765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.